Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Bailey

Pediatrics Lafayette, LA Medical Doctor

NPI 1265430656 CMS profile 969513

5000 Ambassador Caffery Pkwy Bldg 12, Lafayette, LA 70508

Open in the dashboard

General payments

$3,540

220 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Bailey of Lafayette, LA is reported in the CMS Open Payments database as having received $3,540 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $625 36
2024 General $725 36
2023 General $353 25
2022 General $569 41
2021 General $337 22
2020 General $330 20
2019 General $601 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Bailey
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Brian Bailey were reported at $625. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Brian Bailey Pediatrics median Middle half National median
2019 $601 $86 $31–$183 $163
2020 $330 $49 $22–$110 $114
2021 $337 $68 $27–$158 $132
2022 $569 $77 $30–$173 $149
2023 $353 $88 $33–$190 $160
2024 $725 $94 $34–$206 $164
2025 $625 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $614 34 payments
  2. Corium, Inc. $402 31 payments
  3. Tris Pharma Inc $348 23 payments
  4. GlaxoSmithKline, LLC. $240 17 payments
  5. Ironshore Pharmaceuticals Inc. $236 14 payments
  6. Adlon Therapeutics L.P. $217 13 payments
  7. Neos Therapeutics, LP $194 11 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $180 10 payments
  9. Merck Sharp & Dohme Corporation $153 11 payments
  10. Sanofi Pasteur Inc. $146 10 payments
  11. Other $810 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,540 220 payments
Products named General payments · program years 2019–2025
  1. Azstarys $402 31 payments
  2. Qelbree Viloxazine Hydrochloride $385 15 payments
  3. QELBREE Psychology $229 19 payments
  4. ADHANSIA XR $217 13 payments
  5. BEXSERO $216 15 payments
  6. PEDIARIX $214 15 payments
  7. VYVANSE $211 12 payments
  8. Dyanavel XR $167 12 payments
  9. COTEMPLA XR-ODT $150 8 payments
  10. GARDASIL 9 $142 10 payments
  11. Other $2,567 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record